See more : First Acceptance Corporation (FACO) Income Statement Analysis – Financial Results
Complete financial analysis of AIkido Pharma Inc. (AIKI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AIkido Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Jiangsu Financial Leasing Co., Ltd. (600901.SS) Income Statement Analysis – Financial Results
- LSB Industries, Inc. (LXU) Income Statement Analysis – Financial Results
- Solitaire Machine Tools Limited (SOLIMAC.BO) Income Statement Analysis – Financial Results
- Syngene International Limited (SYNGENE.NS) Income Statement Analysis – Financial Results
- Agrico Acquisition Corp. (RICO) Income Statement Analysis – Financial Results
AIkido Pharma Inc. (AIKI)
About AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 9.00K | 28.00K | 1.24M | 877.00K | 33.00K | 10.00K | 27.00K | 19.92K | 820.93K | 1.43M | 1.36M | 1.03M | 154.70K | 24.84M | 23.05M | 22.35M | 18.09M | 15.13M | 19.94M | 17.03M | 12.70M | 16.00M | 13.60M | 13.80M | 13.70M | 16.00M | 13.60M | 16.70M | 15.10M | 15.90M | 15.30M | 13.60M | 10.50M | 8.00M | 6.70M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 81.00K | 92.00K | 84.00K | 88.00K | 864.00K | 3.00K | 0.00 | 388.07K | 517.68K | 449.29K | 397.65K | 54.29K | 20.79M | 17.93M | 17.36M | 12.60M | 11.55M | 13.64M | 11.09M | 9.60M | 12.50M | 9.90M | 9.60M | 9.90M | 12.90M | 10.40M | 13.20M | 12.40M | 13.30M | 12.90M | 11.10M | 7.70M | 5.90M | 5.20M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 9.00K | -53.00K | 1.14M | 793.00K | -55.00K | -854.00K | 24.00K | 19.92K | 432.86K | 914.78K | 909.82K | 628.32K | 100.41K | 4.04M | 5.12M | 4.99M | 5.48M | 3.58M | 6.30M | 5.95M | 3.10M | 3.50M | 3.70M | 4.20M | 3.80M | 3.10M | 3.20M | 3.50M | 2.70M | 2.60M | 2.40M | 2.50M | 2.80M | 2.10M | 1.50M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% | -189.29% | 92.56% | 90.42% | -166.67% | -8,540.00% | 88.89% | 100.00% | 52.73% | 63.86% | 66.94% | 61.24% | 64.90% | 16.28% | 22.21% | 22.31% | 30.32% | 23.66% | 31.59% | 34.91% | 24.41% | 21.88% | 27.21% | 30.43% | 27.74% | 19.38% | 23.53% | 20.96% | 17.88% | 16.35% | 15.69% | 18.38% | 26.67% | 26.25% | 22.39% |
| Research & Development | 830.00K | 559.00K | 2.49M | 2.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 727.09K | 1.65M | 4.85M | 6.83M | 4.00M | 5.87M | 883.61K | 288.11K | 196.36K | 423.17K | 476.00K | 390.16K | 281.08K | 300.00K | 400.00K | 600.00K | 600.00K | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.68M | 7.73M | 4.06M | 0.00 | 3.06M | 3.69M | 4.58M | 5.13M | 20.79M | 15.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.68M | 7.73M | 4.06M | 3.17M | 3.06M | 3.69M | 4.58M | 5.13M | 20.79M | 15.07M | 2.76M | 3.13M | 4.08M | 3.27M | 3.14M | 3.87M | 5.64M | 5.14M | 5.36M | 5.83M | 4.51M | 4.03M | 3.94M | 3.70M | 3.80M | 2.80M | 2.50M | 2.30M | 2.70M | 2.00M | 1.90M | 2.10M | 2.30M | 2.30M | 1.60M | 1.30M | 1.20M | 1.10M |
| Other Expenses | 1.83M | 1.15M | 1.47M | 0.00 | 1.44M | 1.37M | 2.14M | 6.32M | 9.83M | 291.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57M | 2.28M | 1.50M | 1.59M | 1.42M | 1.31M | 1.70M | 1.30M | 600.00K | 700.00K | 500.00K | 400.00K | 500.00K | 600.00K | 600.00K | 600.00K | 500.00K | 500.00K | 400.00K | 300.00K | 200.00K |
| Operating Expenses | 14.35M | 9.44M | 6.55M | 5.69M | 4.50M | 5.06M | 6.72M | 11.44M | 30.62M | 15.37M | 3.49M | 4.78M | 8.93M | 10.10M | 7.14M | 9.74M | 6.52M | 8.00M | 7.83M | 7.76M | 6.58M | 5.84M | 5.54M | 5.70M | 5.50M | 4.00M | 3.80M | 3.30M | 3.10M | 2.50M | 2.50M | 2.70M | 2.90M | 2.80M | 2.10M | 1.70M | 1.50M | 1.30M |
| Cost & Expenses | 14.35M | 9.44M | 6.55M | 5.69M | 4.50M | 5.06M | 6.72M | 11.44M | 30.62M | 15.37M | 3.49M | 5.17M | 9.44M | 10.55M | 7.54M | 9.79M | 27.32M | 25.93M | 25.19M | 20.36M | 18.13M | 19.48M | 16.62M | 15.30M | 18.00M | 13.90M | 13.40M | 13.20M | 16.00M | 12.90M | 15.70M | 15.10M | 16.20M | 15.70M | 13.20M | 9.40M | 7.40M | 6.50M |
| Interest Income | 687.00K | 252.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.46K | 6.11K | 37.65K | 348.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.76M | -2.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.00K | 2.22K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -188.00K | 2.27M | -5.79M | 1.50M | 1.44M | 1.38M | 2.14M | 6.32M | 9.83M | 291.00K | 63.68K | 69.83K | 77.87K | 84.38K | 85.72K | 210.42K | 2.60M | 2.57M | 2.28M | 1.50M | 1.59M | 1.42M | 1.31M | 1.70M | 1.30M | 600.00K | 700.00K | 500.00K | 400.00K | 500.00K | 600.00K | 600.00K | 600.00K | 500.00K | 500.00K | 400.00K | 300.00K | 200.00K |
| EBITDA | -14.35M | -7.17M | -12.34M | -4.18M | 3.17M | -1.93M | -4.34M | -45.15M | -20.70M | -17.67M | -3.79M | -3.38M | -7.79M | -9.06M | -4.60M | -4.14M | 6.22M | -274.50K | -544.36K | -753.77K | -1.33M | 1.99M | 1.91M | -3.20M | -800.00K | 400.00K | 900.00K | 1.00M | 400.00K | -100.00K | 1.70M | 800.00K | 300.00K | 100.00K | 800.00K | 1.30M | 800.00K | 300.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -46,477.78% | 11,321.43% | -156.15% | -494.64% | -136,809.09% | -207,010.00% | -65,459.26% | -19,041.00% | -411.41% | -543.93% | -666.93% | -448.40% | -2,673.58% | 25.04% | -1.19% | -2.44% | -4.17% | -8.78% | 9.99% | 11.19% | -25.20% | -5.00% | 2.94% | 6.52% | 7.30% | 2.50% | -0.74% | 10.18% | 5.30% | 1.89% | 0.65% | 5.88% | 12.38% | 10.00% | 4.48% |
| Operating Income | -14.35M | -9.44M | -6.55M | -5.69M | -6.87M | -3.82M | -8.55M | -52.01M | -30.61M | -15.35M | -3.47M | -4.35M | -8.01M | -9.19M | -6.51M | -9.64M | -2.48M | -2.89M | -2.85M | -2.27M | -3.00M | 453.77K | 411.05K | -2.60M | -2.00M | -300.00K | 400.00K | 500.00K | 0.00 | 700.00K | 1.00M | 200.00K | -300.00K | -400.00K | 400.00K | 1.10M | 600.00K | 200.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -63,166.67% | -24,550.00% | -309.22% | -975.03% | -157,606.06% | -306,110.00% | -56,840.74% | -17,427.99% | -529.51% | -559.28% | -675.90% | -634.68% | -6,229.60% | -9.98% | -12.52% | -12.73% | -12.58% | -19.85% | 2.28% | 2.41% | -20.47% | -12.50% | -2.21% | 2.90% | 3.65% | 0.00% | 5.15% | 5.99% | 1.32% | -1.89% | -2.61% | 2.94% | 10.48% | 7.50% | 2.99% |
| Total Other Income/Expenses | -7.76M | 2.27M | -5.79M | 1.50M | 8.60M | 516.00K | 2.08M | 545.00K | 79.00K | -2.62M | 583.97K | 899.72K | 142.02K | 37.65K | 340.23K | 377.98K | 6.10M | 37.15K | 23.45K | 17.88K | 81.07K | 114.06K | 0.00 | -2.30M | -100.00K | 100.00K | -200.00K | 0.00 | 0.00 | -100.00K | 100.00K | 0.00 | -300.00K | -100.00K | -100.00K | -200.00K | -100.00K | 0.00 |
| Income Before Tax | -22.11M | -7.17M | -12.34M | -4.18M | 1.73M | -3.31M | -6.48M | -51.47M | -30.53M | -17.97M | -2.89M | -3.45M | -7.87M | -9.15M | -6.17M | -9.26M | 3.62M | -2.85M | -2.82M | -2.26M | -2.92M | 567.82K | 0.00 | -4.90M | -2.10M | -200.00K | 200.00K | 500.00K | 0.00 | 600.00K | 1.10M | 200.00K | -600.00K | -500.00K | 300.00K | 900.00K | 500.00K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -46,477.78% | 6,167.86% | -267.48% | -738.43% | -155,954.55% | -305,320.00% | -66,537.04% | -14,496.70% | -419.91% | -549.37% | -673.13% | -601.52% | -5,985.26% | 14.57% | -12.36% | -12.63% | -12.48% | -19.31% | 2.85% | 0.00% | -38.58% | -13.13% | -1.47% | 1.45% | 3.65% | 0.00% | 4.41% | 6.59% | 1.32% | -3.77% | -3.27% | 2.21% | 8.57% | 6.25% | 0.00% |
| Income Tax Expense | 7.76M | -2.27M | 0.00 | 0.00 | 8.60M | 516.00K | 2.08M | 545.00K | 79.00K | -2.62M | 583.97K | 14.49K | -133.19K | 37.65K | -552.80K | -3.41M | 105.05K | 37.15K | 23.45K | 17.88K | 81.12K | 114.06K | 0.00 | 300.00K | -100.00K | -100.00K | 100.00K | 100.00K | 100.00K | 200.00K | 400.00K | 100.00K | -200.00K | -200.00K | 100.00K | 400.00K | 200.00K | 0.00 |
| Net Income | -29.87M | -4.90M | -12.34M | -4.18M | 1.73M | -3.31M | -6.48M | -51.47M | -30.53M | -17.97M | -3.86M | -3.46M | -7.74M | -9.15M | -4.14M | -938.37K | 3.51M | -2.85M | -2.82M | -2.26M | -2.92M | 567.82K | 591.07K | -5.20M | -2.00M | -100.00K | 100.00K | 400.00K | -100.00K | -800.00K | 700.00K | 100.00K | -400.00K | -300.00K | 200.00K | 500.00K | 300.00K | 100.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -46,477.78% | 6,167.86% | -267.48% | -738.43% | -155,954.55% | -305,320.00% | -66,537.04% | -19,360.63% | -421.68% | -540.07% | -673.13% | -403.09% | -606.58% | 14.14% | -12.36% | -12.63% | -12.48% | -19.31% | 2.85% | 3.47% | -40.94% | -12.50% | -0.74% | 0.72% | 2.92% | -0.63% | -5.88% | 4.19% | 0.66% | -2.52% | -1.96% | 1.47% | 4.76% | 3.75% | 1.49% |
| EPS | -5.60 | -2.97 | -7.47 | -28.31 | 15.48 | -43.13 | -126.45 | -2.20K | -2.12K | -18.73K | -19.38K | -36.06K | -117.22K | -147.56K | -79.53K | -18.05K | 70.26K | -63.31K | -64.14K | -53.73K | -71.27K | 14.56K | 15.16K | -148.57K | -60.61K | -3.13K | 3.45K | 13.79K | -3.57K | -28.57K | 25.00K | 3.57K | -14.29K | -10.71K | 7.14K | 17.86K | 10.71K | 3.57K |
| EPS Diluted | -5.60 | -2.97 | -7.47 | -28.31 | 15.48 | -43.13 | -121.90 | -2.20K | -2.12K | -18.73K | -19.38K | -36.06K | -117.22K | -147.56K | -79.53K | -18.05K | 70.26K | -63.31K | -64.14K | -53.73K | -71.27K | 14.56K | 15.16K | -148.57K | -60.61K | -3.13K | 3.45K | 13.79K | -3.57K | -28.57K | 25.00K | 3.57K | -14.29K | -10.71K | 7.14K | 17.86K | 10.71K | 3.57K |
| Weighted Avg Shares Out | 5.33M | 1.65M | 1.65M | 147.74K | 111.57K | 76.66K | 51.21K | 23.44K | 14.38K | 959.00 | 199.00 | 96.00 | 66.00 | 62.00 | 52.00 | 52.00 | 50.00 | 45.00 | 44.00 | 42.00 | 41.00 | 39.00 | 39.00 | 35.00 | 33.00 | 32.00 | 29.00 | 29.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 |
| Weighted Avg Shares Out (Dil) | 5.33M | 1.65M | 1.65M | 147.74K | 111.57K | 76.66K | 53.13K | 23.44K | 14.38K | 959.00 | 199.00 | 96.00 | 66.00 | 62.00 | 52.00 | 52.00 | 50.00 | 45.00 | 44.00 | 42.00 | 41.00 | 39.00 | 39.00 | 35.00 | 33.00 | 32.00 | 29.00 | 29.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 |
AIkido Pharma Has Pending Data Results on June 4th, with Strongest Balance Sheet in Its History While Trading Below Cash
New York, New York--(Newsfile Corp. - May 20, 2021) - PCG Digital -- Anthony Hayes is an optimist, with good reason. The CEO of AIkido Pharmaceuticals (NASDAQ: AIKI), according to the company's Q1 report and a press release recently issued,...
AIkido Pharma Announces Phase 1 Data To Be Presented at the American Society of Clinical Oncology ("ASCO") Annual Meeting
NEW YORK, May 20, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that Phase 1 testing data will be presented at the 2021 ASCO Annual Meeting June 4, 2021. The presentation of the data will...
7 Reddit Penny Stocks Promising to Cure Cancer
These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on InvestorPlace.
AIKI's Near Term Catalyst Approaching this Quarter with Strong Cash Balance Sheet for Strategic Initiatives
New York, New York--(Newsfile Corp. - May 13, 2021) - PCG Digital -- Things seem to be heating up for (NASDAQ: AIKI) with a near term potential catalyst quickly approaching this quarter and several others planned throughout the remainder of...
AIkido Pharma Inc. Announces First Quarter 2021 Results and Provides Corporate Update
NEW YORK, May 11, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. Anthony Hayes, CEO of AIkido Pharma, stated, "With...
Top Biotech Penny Stocks on Reddit? Check These 3 Out
Biotech penny stocks are back in focus; should these 3 be on your watchlist? The post Top Biotech Penny Stocks on Reddit?
4 Reddit Penny Stocks To Buy On Robinhood For Under $1 Right Now
Penny stocks on Robinhood are a big focus for Reddit traders in April The post 4 Reddit Penny Stocks To Buy On Robinhood For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information |...
Biotech Penny Stocks To Buy? 3 to Watch Under $5
Biotech stocks are more popular than ever; here are 3 to watch under $5 The post Biotech Penny Stocks To Buy? 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
AIkido Pharma Notes Advancement in Radiopharmaceutical Research
NEW YORK, April 16, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today noted that a recent study announced positive early results from a PSMA 617-Lu177 study conducted by a leading global pharmaceutical company. The report provides...
AIkido Pharma Provides Business Update
NEW YORK, April 5, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a business update. Anthony Hayes, CEO of AIkido Pharma, stated, "AIkido's primary focus is the commercialization of improved treatments for multiple types of...
Source: https://incomestatements.info
Category: Stock Reports